A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
NCT00866047
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
58
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Interventions
DRUG:
brentuximab vedotin
Sponsor
Seagen Inc.
Collaborators
[object Object]